Drugs / uracil-tegafur
last change Dec 2019 re-read 2 minutes ago

uracil-tegafur

also known as UFT
Developed for
colorectal cancer · urinary bladder cancer
Investigated by
Eastern Cooperative Oncology Group · National Cancer Institute (NCI) · Urological Oncology Council of Northern Tokyo

Trials 2 · a red edge is where a trial was stopped

2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT00004860 Oct 2000 → Oct 2005 colorectal cancer Eastern Cooperative Oncology Group Completed No outcome recorded
Phase 31 trial
Phase 3 NCT01082510 Jan 2010 → Dec 2017 urinary bladder cancer Urological Oncology Council of Northern Tokyo Unknown No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as uracil-tegafur “PURPOSE: To evaluate the tolerability and effectiveness of uracil-tegafur (UFT) with leucovorin (LV) in the treatment of elderly patients with advanced colorectal cancer.” PMID 18048821 Dec 2007
1

NCT01082510

Known as UFT “PURPOSE: To evaluate the tolerability and effectiveness of uracil-tegafur (UFT) with leucovorin (LV) in the treatment of elderly patients with advanced colorectal cancer.” PMID 18048821 Dec 2007
Route Oral “UFT 100 mg/m2 plus LV 30 mg orally every 8 hours for 28 days every 35 days was administered until progression.” PMID 18048821 Dec 2007